



#34  
10-2303

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: McDONALD et al.

Serial No.: 09/360,242

Filed: July 22, 1999

For: *METHODS AND COMPOSITIONS FOR  
TREATING SECONDARY TISSUE DAMAGE  
AND OTHER INFLAMMATORY  
CONDITIONS AND DISORDERS*

Art Unit: 1647

Examiner: Landsman, R.

I hereby certify that this paper and the attached  
papers are being deposited with the United States  
Postal Service as first class mail in an envelope  
addressed to:

Commissioner for Patents  
U.S. Patent and Trademark Office  
P. O. Box 2327  
Arlington, VA 22202

10/09/02  
Date

Stephanie Seidman

AMENDMENT

Commissioner for Patents  
U.S. Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

RECEIVED

OCT 18 2002

TECH CENTER 1600/2900

Dear Sir:

Responsive to the Office Action, mailed April 9, 2002, entry of the  
amendments and consideration of the following remarks are respectfully  
requested.

IN THE CLAIMS:

Please add claims 88-91 as follows:

88. (New) The method of claim 29, wherein the chemokine receptor  
targeting agent is selected from the group consisting of IL-8, GRO- $\alpha$ , GRO- $\beta$ , IP-  
10, SDF-1 $\beta$ , MCP-1 MCP-3, eotaxin-1, eotaxin-2 and rantes.

E! 89. (New) The method of claim 38, wherein the chemokine receptor  
targeting agent is selected from the group consisting of IL-8, GCP-2, GRO- $\alpha$ ,  
GRO- $\beta$ , GRP- $\gamma$ , ENA-78, PBP, CTAP III, NAP-2, LAPF-4, MIG, PF4, IP-10, SDF-  
1 $\alpha$ , SDF-1 $\beta$ , SDF-2, MCP-1, MCP-2, MCP-3, MCP-4, MCP-5, MIP-1 $\alpha$ , MIP-1 $\beta$ ,  
MIP-1 $\gamma$ , MIP-2, MIP-2 $\alpha$ , MIP-3 $\alpha$ , MIP-3 $\beta$ , MIP-4, MIP-5, MDC, HCC-1, LD78 $\beta$ ,  
eotaxin-1, eotaxin-2, I-309, SCYA17, TARC, RANTES, DC-CK-1, lymphotactin,  
and fractalkine.